The pursuit of reduced-intensity treatments for testicular cancer continued with vigour in 2013. For those with metastatic disease and poor prognoses, an alternative to bleomycin, etoposide and cisplatin chemotherapy emerged. These advances suggest we are making progress by reducing treatment intensity with personalized approaches for this highly curable malignancy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol. 15, 594–603 (1997).
Feldman, D. R., Bosl, G. J., Sheinfeld, J. & Motzer, R. J. Medical treatment of advanced testicular cancer. JAMA 299, 672–684 (2008).
Fizazi, K., Pagliaro, L. C., Flechon, A. & Mardiak, J. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13 [abstract LBA4500]. J. Clin. Oncol. 31 (Suppl.), LBA4500 (2013).
Olofsson, S. E. et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J. Clin. Oncol. 29, 2032–2039 (2011).
Fizazi, K. et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J. Clin. Oncol. 22, 3868–3876 (2004).
Oldenburg, J. et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 (Suppl. 6), vi125–vi132 (2013).
Horwich, A., Dearnaley, D. P., Sohaib, A., Pennert, K. & Huddart, R. A. Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann. Oncol. 24, 2104–2107 (2013).
Tandstad, T. et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J. Clin. Oncol. 27, 2122–2128 (2009).
Tandstad, T. et al. One course of adjuvant BEP in clinical stage I, nonseminoma: mature and expanded results from the SWENOTECA group [abstract 4553]. J. Clin. Oncol. 31 (Suppl.), a4553 (2013).
Fung, C., Fosså, S. D., Milano, M. T., Oldenburg, J. & Travis, L. B. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J. Clin. Oncol. 31, 3807–3814 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Oldenburg, J., Fosså, S. Towards personalized medicine—are we there yet?. Nat Rev Urol 11, 68–69 (2014). https://doi.org/10.1038/nrurol.2013.298
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.298
This article is cited by
-
The importance of personalized medicine in urological cancers
Journal of Diabetes & Metabolic Disorders (2022)
-
The discovery and development of microbial bleomycin analogues
Applied Microbiology and Biotechnology (2018)